A 12 week treatment, multi-centre, randomized, double-blind, parallel-group, active controlled study to assess the efficacy, safety, and tolerability of a fixed dose combination of glycopyrronium (12.5 mcg)/ formoterol fumarate dihydrate (12 mcg) in a dry powder inhaler in comparison with Glenmark AirzTM Glycopyrronium powder for inhalation 50 mcg in subjects with chronic obstructive pulmonary disease

Trial Profile

A 12 week treatment, multi-centre, randomized, double-blind, parallel-group, active controlled study to assess the efficacy, safety, and tolerability of a fixed dose combination of glycopyrronium (12.5 mcg)/ formoterol fumarate dihydrate (12 mcg) in a dry powder inhaler in comparison with Glenmark AirzTM Glycopyrronium powder for inhalation 50 mcg in subjects with chronic obstructive pulmonary disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 May 2017

At a glance

  • Drugs Formoterol/glycopyrrolate (Primary) ; Glycopyrrolate
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Glenmark Pharmaceuticals Ltd
  • Most Recent Events

    • 22 May 2017 Status changed from not yet recruiting to recruiting.
    • 09 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top